BeOne Medicines (ONC) Return on Invested Capital (2016 - 2026)
BeOne Medicines (ONC) posted quarterly Return on Invested Capital of 0.0% for Q1 2026, up 1.0% year-over-year from 0.0% in Q1 2025, and up 167.16% quarter-over-quarter from 0.0% in Q4 2025.
BeOne Medicines (ONC) Return on Invested Capital (2016 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Return on Invested Capital for 11 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Invested Capital rose 1.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (up 1.0% YoY), while the FY2025 annual figure was 0.01%, up 2.0% from the prior year.
- Return on Invested Capital improved to 0.0% in Q1 2026 per ONC's latest filing, from 0.0% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.0% in Q1 2026 and bottomed at 0.01% in Q1 2023.
- Historically, Return on Invested Capital has averaged 0.01% across 5 years, with a median of 0.01% in 2024.
- On a YoY basis, Return on Invested Capital climbed as much as 1 bps in 2022 and fell as far as 1 bps in 2022.
- BeOne Medicines' Return on Invested Capital stood at 0.01% in 2022, then grew by 26 bps to 0.01% in 2023, then jumped by 77 bps to 0.0% in 2024, then surged by 171 bps to 0.0% in 2025, then surged by 167 bps to 0.0% in 2026.
- Business Quant data shows ONC's Return on Invested Capital at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00% |
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | -0.01% |
| Dec 31, 2023 | -0.01% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | -0.01% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | -0.01% |